Full text is available at the source.
Abstract
Obesity and type 2 diabetes mellitus (T2DM) share mechanisms that affect glucose metabolism and insulin resistance.
- SGLT2 inhibitors and GLP-1 receptor agonists are recommended for overweight or obese patients with T2DM due to beneficial effects.
- The influence of baseline obesity on the glycemic response to these treatments in real-world settings is uncertain.
- Further research may be needed to clarify the relationship between obesity and the effectiveness of these diabetes medications.
Simplified